Reboli is dean of Cooper Medical School in Camden, one of the most competitive medical schools in the country. Cooper moreover is part of the so-called “Eds and Meds” strategy being employed in Camden, based on the theory that health care and higher education can serve as key anchor institutions to revitalize the city’s struggling economy.
Rebeli is no stranger to this list, having earned the No. 9 spot in the 2019 edition of the Education Power 50, and a No. 8 spot last year. One insider previously credited her as a key player in broadening Cooper Medical School’s name from one with just local recognition to a national leader.
That status matters a great deal in the fight against the mutating COVID-19 virus and the litany of public health vulnerabilities the pandemic has exposed over the past 18 months. In August, hundreds of new students began their medical training at Cooper — a generation entering an entirely new, post-COVID era of medicine. And it’s Reboli who’s the chief academic officer with responsibility for all areas in the school.
Reboli previously served as a consultant to Janssen, Vicuron, Pfizer, and Merck Pharmaceutical Company on antimicrobial drug development and clinical trial design. She spent years honing her craft on the study of infectious diseases and epidemiology, having headed Cooper’s own division focused on just that field of study. That’s made her a frequent source of insight for how the state and national health care infrastructure can navigate the pandemic.
